Vaccine offers current defense against equine influenza
FLORHAM PARK, N.J. — Zoetis has partnered with the renowned Gluck Equine Research Center at the University of Kentucky to show that FLUVAC INNOVATOR, the first equine influenza virus (EIV) vaccine, can provide a demonstrated cross-reactive immune response against emerging EIV strains.
Their most recent study demonstrated an immune response against Richmond 07. Although Richmond 07 is not circulating in the United States, it might be a threat to horses with international exposure. Zoetis put FLUVAC INNOVATOR to the test, and it succeeded.
To help ensure vaccines offer current protection, the World Organisation for Animal Health (OIE) encourages vaccine manufacturers to work with laboratories, such as the Gluck Center, that can test for reactivity against circulating strains.
In fact, the FLUVAC INNOVATOR line of vaccines sets the standard for equine influenza vaccine protection. With test studies against six EIV strains since 2002, Zoetis continues its legacy of evaluating the FLUVAC INNOVATOR line of vaccines to help ensure the most relevant protection.
This commitment to providing an immunologically current EIV vaccine has made FLUVAC INNOVATOR the most trusted EIV line of vaccines, as well as the market leader.
After all, the best way to help protect horses against EIV is to vaccinate before exposure to this highly contagious respiratory disease. And that’s why horse owners can depend on the FLUVAC INNOVATOR vaccine line, because it helps offer demonstrated protection against EIV and is backed by the Zoetis commitment to continuously monitor and evaluate the efficacy and safety of its products.
For more information on FLUVAC INNOVATOR, contact your veterinarian or visit fluvacinnovator.com. Learn more about other Zoetis equine products at zoetisUS.com.